Opioid Use Disorder Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Distribution Channel, Drug), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Opioid Use Disorder Market size stood at USD 5.7 Billion in 2025 and is predicted to grow at a 11% CAGR from 2026 to 2035, attaining USD 16.18 Billion by 2035. The industry revenue for 2026 is assessed at USD 6.26 billion.
Get more details on this report
Request Free Sample ReportOpioid Use Disorder Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 66.91% share in 2025, supported by mature treatment infrastructure, medication-assisted treatment availability, and established reimbursement pathways.
- Europe is projected to grow at a 12.32% CAGR, driven by structured treatment models, wider evidence-based care access, and integration of therapy with rehabilitation services.
Segment Momentum
- Injectable Administration held a 62.22% market share in 2025 because long-acting dosing supports treatment adherence, consistent administration, and supervised care, making it well suited for structured clinical management and treatment continuity.
- Retail Pharmacies are expanding rapidly as ongoing treatment increasingly shifts to community settings. Their convenience, wider reach, and easier refill access support routine outpatient medication management and continued therapy.
Market Expansion Drivers
- Rising prevalence of substance use disorders increasing demand for medication-assisted treatment solutions.
- Expanding government funding and public health initiatives improving access to addiction treatment services.
- Growing integration of opioid treatment programs into primary care settings expanding patient outreach.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major players in the opioid use disorder market include Indivior PLC (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Collegium Pharmaceutical, Inc. (USA), Alkermes plc (Ireland), Orexo AB (Sweden), Camurus AB (Sweden), Hikma Pharmaceuticals PLC (Jordan).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the number of people affected by opioid dependence and related substance use conditions rises, treatment systems face sustained pressure to move beyond short-term detoxification toward longer-duration pharmacological care. This is increasing demand for the opioid use disorder market by increasing utilization of medication-assisted treatment options such as buprenorphine, methadone, and naltrexone, particularly where relapse risk, overdose exposure, and co-occurring behavioral health needs make medication support clinically necessary. In practice, higher patient volumes push providers, payers, and health systems to expand prescribing capacity, treatment slots, and care coordination models, reinforcing market demand for approved therapies and associated treatment services.
Expanding government funding and public health initiatives improving access to addiction treatment services
Public funding and targeted health initiatives are reducing some of the main barriers that have historically limited treatment uptake, including affordability, provider availability, and uneven geographic access. In the opioid use disorder market, this translates into broader reimbursement coverage, support for community clinics and recovery programs, and policy-backed efforts to expand screening, referral, and continuity of care. These measures influence market adoption by bringing more patients into formal treatment pathways and by making it more viable for healthcare organizations to invest in medication-assisted treatment infrastructure, supporting market expansion through stronger service delivery capacity.
Growing integration of opioid treatment programs into primary care settings expanding patient outreach
The shift of opioid use disorder care into primary care is changing how patients enter treatment, especially among individuals who are unlikely to engage with standalone addiction centers because of stigma, travel constraints, or fragmented referral processes. For the opioid use disorder market, integration into routine medical settings increases market penetration by embedding screening, diagnosis, medication prescribing, and follow-up into familiar points of care where chronic conditions are already managed. This practical change broadens the prescriber base, improves earlier intervention, and raises treatment continuity, strengthening market development through more consistent patient engagement and refill persistence.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of substance use disorders increasing demand for medication-assisted treatment solutions | 2.00% | High | North America, Europe | High | Near Term |
| Expanding government funding and public health initiatives improving access to addiction treatment services | 1.90% | High | North America | High | Near Term |
| Growing integration of opioid treatment programs into primary care settings expanding patient outreach | 1.40% | Moderate | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional position in 2025, accounting for a 66.91% share of the opioid use disorder market. This leadership is sustained by the region’s established treatment infrastructure, broader availability of medication-assisted treatment, and comparatively mature reimbursement and care delivery pathways that support patient access across clinical settings. Market activity is also reinforced by ongoing demand for long-term management solutions, as providers, payers, and public health systems continue to integrate screening, prescribing, counseling, and follow-up services into routine addiction care.
Europe is projected to expand at a 12.32% CAGR over the forecast period in the opioid use disorder market, driven by the widening adoption of structured treatment models and stronger regional focus on improving access to evidence-based care. Growth is being propelled by the gradual expansion of treatment availability through public health systems, alongside increasing practical integration of pharmacological therapy with rehabilitation and harm-reduction services. As more patients move into formal care pathways and treatment delivery becomes more standardized across countries, regional demand is accelerating in a measurable way.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Structured rehabilitation pathwaysGermany’s opioid use disorder market is supported by structured rehabilitation and substitution therapy programs within regulated healthcare settings. Providers in Germany focus on coordinated treatment models that combine pharmacological and psychosocial support services.
France 🇫🇷
Public healthcare interventionFrance’s opioid use disorder market is supported by public healthcare-driven intervention programs and harm reduction strategies. In France, treatment systems emphasize accessibility to substitution therapies and long-term patient support frameworks.
Italy 🇮🇹
Community care coordinationItaly’s opioid use disorder market is shaped by community-based care coordination and rehabilitation services delivered through regional health systems. Providers in Italy focus on improving treatment continuity between hospital care and outpatient support networks.
Japan 🇯🇵
Controlled clinical managementJapan’s opioid use disorder market is characterized by tightly regulated clinical management and hospital-based treatment frameworks. In Japan, healthcare providers emphasize controlled therapeutic protocols and careful patient monitoring within specialist care environments.
South Korea 🇰🇷
Clinical treatment integrationSouth Korea’s opioid use disorder market is evolving with increased integration of addiction treatment into mainstream clinical services. Hospitals in South Korea are focusing on multidisciplinary care approaches combining psychiatry, counseling, and pharmacotherapy.
United States 🇺🇸
Treatment access expansionIn the U.S., opioid use disorder treatment is increasingly centered on expanding access to medication-assisted therapies and integrated care programs. Healthcare systems prioritize continuity of care, with strong emphasis on outpatient treatment pathways and behavioral health integration.
Segment Leadership and Growth Trends
Opioid Use Disorder Market Share (%), Route of Administration, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportInjectable Administration held a 62.22% share of the opioid use disorder market in 2025, reflecting its established role in treatment settings where adherence, dosing consistency, and supervised care remain central to patient management. its position is maintained through the practical advantage of long-acting administration in reducing missed doses and supporting structured treatment pathways, especially for patients requiring close clinical oversight. The same operating benefits are also driving continued momentum in the opioid use disorder market, as providers increasingly favor administration routes that fit monitored care models and help address the day-to-day challenges of treatment continuity relative to less controlled alternatives.
Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)
Within the opioid use disorder market, Hospital Pharmacies accounted for a 50.77% share in 2025, underpinned by their close integration with inpatient care, emergency treatment, and specialist-led addiction management. Their leading share reflects the operational reality that opioid use disorder therapies often begin or stabilize in hospital-linked settings where prescribing, monitoring, and follow-up can be coordinated more tightly. This channel remains dominant because it aligns with clinically supervised treatment initiation and the handling of patients with more complex care needs.
Retail Pharmacies are emerging as the fastest-growing distribution channel in the opioid use disorder market as treatment access increasingly shifts toward community-based and ongoing maintenance care. Their momentum comes from practical convenience, broader geographic reach, and easier refill access for patients continuing therapy outside acute care settings. Compared with hospital-based dispensing, retail pharmacies are better positioned to support recurring medication access in routine outpatient treatment, which is strengthening their growth trajectory.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Oral Administration, Injectable Administration, Others | Injectable Administration | Injectable Administration |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Others | Hospital Pharmacies | Retail Pharmacies |
| Drug | Naltrexone, Buprenorphine, Methadone, Others | Buprenorphine | Buprenorphine |
Competitive Landscape and Market Positioning
1. Indivior PLC (United Kingdom)
2. Teva Pharmaceutical Industries Ltd. (Israel)
3. Collegium Pharmaceutical Inc. (USA)
4. Alkermes plc (Ireland)
5. Orexo AB (Sweden)
6. Camurus AB (Sweden)
7. Hikma Pharmaceuticals PLC (Jordan)
Ongoing efforts to improve addiction treatment outcomes are influencing developments in the opioid use disorder market. Industry participants are focusing on long-acting therapies, patient adherence solutions, and integrated behavioral treatment approaches to enhance recovery effectiveness. Regulatory support for expanded treatment accessibility and harm reduction initiatives is also encouraging therapeutic innovation within the sector.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Indivior PLC | Mar-23 | Indivior PLC completed the strategic acquisition of Opiant Pharmaceuticals, Inc. to enhance its portfolio of opioid addiction and overdose treatment solutions. This transaction significantly strengthens Indivior's competitive positioning and expands its pipeline of therapeutic assets aimed at addressing the critical requirements for effective opioid use disorder management. |
| Titan Pharmaceuticals, Inc. | Jul-23 | Titan Pharmaceuticals entered into an asset purchase agreement with Fedson, Inc. to divest its ProNeura technology assets. This sale included its portfolio of addiction treatment medications and early-stage drug delivery projects, specifically impacting the development programs for Nalmefene and Probuphine implants, marking a strategic shift in the company’s focus. |
| Be Well Texas | Jul-25 | The Texas Health and Human Services Commission awarded $256 million to Be Well Texas to scale opioid use disorder treatment services statewide. This major investment focuses on expanding access to medications such as naloxone, enhancing recovery support infrastructure, and strengthening addiction care delivery networks to serve both rural and urban populations more effectively. |
| U.S. Department of Health and Human Services | Feb-26 | The U.S. Department of Health and Human Services launched the $100 million STREETS Initiative to strengthen the national response to opioid addiction. The federal funding aims to expand evidence-based treatment access, improve clinical recovery support systems, and bolster community-level interventions to reduce mortality rates and enhance the overall continuity of care for affected populations. |
| Acadia Healthcare | Oct-24 | Acadia Healthcare acquired three behavioral health facilities to expand its operational footprint in the addiction treatment sector. This acquisition supports the company’s geographic expansion strategy and integrates additional capacity for delivering medication-assisted treatment and comprehensive behavioral health services, reinforcing its market position as a key provider of integrated addiction recovery programs. |
| Highmark Wholecare; Ophelia | Apr-24 | Highmark Wholecare and Ophelia formed a partnership to address treatment access gaps for Medicaid enrollees. By integrating payer support with a digital-first addiction treatment platform, the collaboration aims to improve entry into medication-assisted treatment programs, enhance care coordination, and reduce health disparities to drive better patient engagement and long-term recovery outcomes. |
| Cedar Recovery | Jul-24 | Cedar Recovery launched CedarRx, an on-site pharmacy model designed to centralize access to addiction treatment medications. This initiative streamlines medication-assisted treatment delivery, reduces logistical barriers for patients, and enhances treatment adherence by integrating pharmacy services directly within the clinical care setting to ensure greater continuity of care. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Opioid Use Disorder Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Opioid Use Disorder Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the opioid use disorder market?
How is the opioid use disorder industry expected to grow over the next 10 years?
How is expanded access to addiction treatment reshaping adoption patterns in the opioid use disorder market?
How is integration of opioid treatment into primary care influencing market growth strategies?
Why is Injectable Administration the leading route of administration in the opioid use disorder market?
Why are Retail Pharmacies the fastest-growing distribution channel in the opioid use disorder market?
Why does North America lead the opioid use disorder market?
How is Europe emerging as a growth region in opioid use disorder care?
Who are the major participants shaping the opioid use disorder landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization